mutLBSgeneDB |
Gene summary for NR1H3 |
Gene summary |
Basic gene Info. | Gene symbol | NR1H3 |
Gene name | nuclear receptor subfamily 1, group H, member 3 | |
Synonyms | LXR-a|LXRA|RLD-1 | |
Cytomap | UCSC genome browser: 11p11.2 | |
Type of gene | protein-coding | |
RefGenes | NM_001130101.2, NM_001130102.2,NM_001251934.1,NM_001251935.1,NM_005693.3, | |
Description | liver X nuclear receptor alpha variant 1oxysterols receptor LXR-alpha | |
Modification date | 20141222 | |
dbXrefs | MIM : 602423 | |
HGNC : HGNC | ||
Ensembl : ENSG00000025434 | ||
HPRD : 07211 | ||
Vega : OTTHUMG00000150628 | ||
Protein | UniProt: Q13133 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_NR1H3 | |
BioGPS: 10062 | ||
Pathway | NCI Pathway Interaction Database: NR1H3 | |
KEGG: NR1H3 | ||
REACTOME: NR1H3 | ||
Pathway Commons: NR1H3 | ||
Context | iHOP: NR1H3 | |
ligand binding site mutation search in PubMed: NR1H3 | ||
UCL Cancer Institute: NR1H3 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0010870 | positive regulation of receptor biosynthetic process | 18511497 | GO:0010875 | positive regulation of cholesterol efflux | 16141411 | GO:0032376 | positive regulation of cholesterol transport | 16141411 | GO:0032570 | response to progesterone | 16141411 | GO:0034145 | positive regulation of toll-like receptor 4 signaling pathway | 18511497 | GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 16141411 | GO:0071222 | cellular response to lipopolysaccharide | 18511497 | GO:2000189 | positive regulation of cholesterol homeostasis | 18511497 |
Top |
Ligand binding site mutations for NR1H3 |
Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.) : non-synonymous mutation on LBS, Circle size denotes number of samples. |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | N225 | R226W | COAD | 3 | F254 | R253H | COAD | 2 | I295 | A294V | COAD | 1 | N225 | Q223L | LUAD | 1 | N225 | R227L | LUAD | 1 | N225 | R226Q | OV | 1 | R283 | R283P | SKCM | 1 | I313,F315 | T314I | SKCM | 1 | N225 | R227H | STAD | 1 | R232 | R234Q | UCEC | 1 | R232 | R232Q | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for NR1H3 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | N225 | R227H | -1.6344547 | R232 | R232Q | -1.2751175 | R232 | R234Q | -1.272859 | N225 | R227L | -0.95243027 | N225 | R226Q | -0.87532468 | F254 | R253H | -0.85721248 | R283 | R283P | -0.57781313 | N225 | R226W | -0.54110446 | I295 | A294V | -0.32887438 | I313 | T314I | -0.24817607 | F315 | T314I | -0.24817607 | N225 | Q223L | -0.13619305 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for NR1H3 from PDB |
PDB ID | PDB title | PDB structure | 1UHL | Crystal structure of the LXRalfa-RXRbeta LBD heterodimer |
Top |
Differential gene expression and gene-gene network for NR1H3 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for NR1H3 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0015695 | Fatty Liver | 3 | Biomarker |
umls:C0008370 | Cholestasis | 1 | Therapeutic |
umls:C0860207 | Drug-Induced Liver Injury | 1 | Therapeutic |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for NR1H3 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Gene-centered drug-gene interaction network |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Experimental | DB07080 | N-(2,2,2-TRIFLUOROETHYL)-N-{4-[2,2,2-TRIFLUORO-1-HYDROXY-1-(TRIFLUOROMETHYL)ETHYL]PHENYL}BENZENESULFONAMIDE | Small molecule | |
Experimental | DB07929 | N-(TERT-BUTYL)-3,5-DIMETHYL-N'-[(5-METHYL-2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)CARBONYL]BENZOHYDRAZIDE | Small molecule | |
Experimental | DB08063 | 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE | Small molecule | |
Experimental | DB08175 | (2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID | Small molecule |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of NR1H3 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 4KQ | 2-[4-[4-[[2-[(2-METHYLPROPAN-2-YL)OXYCARBONYL]-3- OXIDANYL-4-(TRIFLUOROMETHYL) PHENYL]METHOXY]PHENYL]PHENYL]ETHANOIC ACID | 5avl | A | F254 I295 F315 | O90 | {3-CHLORO-4-[(3-{[7-PROPYL-3-(TRIFLUOROMETHYL)-1,2-BENZISOXAZOL-6-YL]OXY}PROPYL)SULFANYL]PHENYL}ACETICACID | 3ips | A | F315 | O90 | {3-CHLORO-4-[(3-{[7-PROPYL-3-(TRIFLUOROMETHYL)-1,2-BENZISOXAZOL-6-YL]OXY}PROPYL)SULFANYL]PHENYL}ACETICACID | 3ips | B | F315 | 4KM | TERT-BUTYL 2-[[4-[ETHANOYL(METHYL) AMINO]PHENOXY]METHYL]-5-(TRIFLUOROMETHYL)BENZOATE | 5avi | A | I295 F315 | 4KM | TERT-BUTYL 2-[[4-[ETHANOYL(METHYL) AMINO]PHENOXY]METHYL]-5-(TRIFLUOROMETHYL)BENZOATE | 5avi | C | I295 F315 | 965 | [3-(3-{[2-CHLORO-3-(TRIFLUOROMETHYL)BENZYL](2,2-DIPHENYLETHYL)AMINO}PROPOXY)PHENYL]ACETIC ACID | 3ipq | A | I295 I313 F315 | O40 | 4-{[METHYL(3-{[7-PROPYL-3-(TRIFLUOROMETHYL)-1,2-BENZISOXAZOL-6-YL]OXY}PROPYL)CARBAMOYL]AMINO}BENZOICACID | 3ipu | A | N225 R232 I295 F315 | O40 | 4-{[METHYL(3-{[7-PROPYL-3-(TRIFLUOROMETHYL)-1,2-BENZISOXAZOL-6-YL]OXY}PROPYL)CARBAMOYL]AMINO}BENZOICACID | 3ipu | B | N225 R232 I295 F315 | III | Peptide ligand (HIS,LYS,ILE,LEU,HIS,ARG,LEU,LEU,GLN,ASP) | 1uhl | B | R283 | III | Peptide ligand (SER,LEU,THR,GLU,ARG,HIS,LYS,ILE,LEU,HIS,ARG,LEU,LEU,GLN,GLU) | 3ipq | A | R283 | III | Peptide ligand (SER,LEU,THR,GLU,ARG,HIS,LYS,ILE,LEU,HIS,ARG,LEU,LEU,GLN,GLU) | 3ips | B | R283 | III | Peptide ligand (SER,LEU,THR,GLU,ARG,HIS,LYS,ILE,LEU,HIS,ARG,LEU,LEU,GLN,GLU) | 3ipu | A | R283 | III | Peptide ligand (SER,LEU,THR,GLU,ARG,HIS,LYS,ILE,LEU,HIS,ARG,LEU,LEU,GLN,GLU) | 3ipu | B | R283 | III | Peptide ligand (SER,LEU,THR,GLU,ARG,HIS,LYS,ILE,LEU,HIS,ARG,LEU,LEU,GLN,GLU) | 5avi | A | R283 | III | Peptide ligand (SER,LEU,THR,GLU,ARG,HIS,LYS,ILE,LEU,HIS,ARG,LEU,LEU,GLN,GLU) | 5avi | C | R283 | III | Peptide ligand (SER,LEU,THR,GLU,ARG,HIS,LYS,ILE,LEU,HIS,ARG,LEU,LEU,GLN,GLU) | 5avl | A | R283 |
Top |
Conservation information for LBS of NR1H3 |
Multiple alignments for Q13133 in multiple species |
LBS | AA sequence | # species | Species | A261 | HFTELAIVSVQ | 3 | Homo sapiens, Mus musculus, Bos taurus | A288 | REDQIALLKTS | 3 | Homo sapiens, Mus musculus, Bos taurus | E284 | LQLSREDQIAL | 3 | Homo sapiens, Mus musculus, Bos taurus | E301 | EVMLLETSRRY | 3 | Homo sapiens, Mus musculus, Bos taurus | E441 | PPLLSEIWDVH | 3 | Homo sapiens, Mus musculus, Bos taurus | F254 | ARQQRFAHFTE | 3 | Homo sapiens, Mus musculus, Bos taurus | F257 | QRFAHFTELAI | 3 | Homo sapiens, Mus musculus, Bos taurus | F278 | KQLPGFLQLSR | 3 | Homo sapiens, Mus musculus, Bos taurus | F315 | SESITFLKDFS | 3 | Homo sapiens, Mus musculus, Bos taurus | F326 | YNREDFAKAGL | 3 | Homo sapiens, Mus musculus, Bos taurus | F335 | GLQVEFINPIF | 3 | Homo sapiens, Mus musculus, Bos taurus | F340 | FINPIFEFSRA | 3 | Homo sapiens, Mus musculus, Bos taurus | H421 | TLSSVHSEQVF | 3 | Homo sapiens, Mus musculus, Bos taurus | I287 | SREDQIALLKT | 3 | Homo sapiens, Mus musculus, Bos taurus | I295 | LKTSAIEVMLL | 3 | Homo sapiens, Mus musculus, Bos taurus | I313 | PGSESITFLKD | 3 | Homo sapiens, Mus musculus, Bos taurus | I336 | LQVEFINPIFE | 3 | Homo sapiens, Mus musculus, Bos taurus | I339 | EFINPIFEFSR | 3 | Homo sapiens, Mus musculus, Bos taurus | K273 | IVDFAKQLPGF | 3 | Homo sapiens, Mus musculus, Bos taurus | K291 | QIALLKTSAIE | 3 | Homo sapiens, Mus musculus, Bos taurus | L260 | AHFTELAIVSV | 3 | Homo sapiens, Mus musculus, Bos taurus | L290 | DQIALLKTSAI | 3 | Homo sapiens, Mus musculus, Bos taurus | L299 | AIEVMLLETSR | 3 | Homo sapiens, Mus musculus, Bos taurus | L316 | ESITFLKDFSY | 3 | Homo sapiens, Mus musculus, Bos taurus | L331 | FAKAGLQVEFI | 3 | Homo sapiens, Mus musculus, Bos taurus | L428 | EQVFALRLQDK | 3 | Homo sapiens, Mus musculus, Bos taurus | L435 | LQDKKLPPLLS | 3 | Homo sapiens, Mus musculus, Bos taurus | L438 | KKLPPLLSEIW | 3 | Homo sapiens, Mus musculus, Bos taurus | L439 | KLPPLLSEIWD | 3 | Homo sapiens, Mus musculus, Bos taurus | M298 | SAIEVMLLETS | 3 | Homo sapiens, Mus musculus, Bos taurus | N225 | AQQQCNRRSFS | 2 | Homo sapiens, Mus musculus | N225 | AQQLCNRRSFS | 1 | Bos taurus | N371 | SADRPNVQDQL | 3 | Homo sapiens, Mus musculus, Bos taurus | P437 | DKKLPPLLSEI | 3 | Homo sapiens, Mus musculus, Bos taurus | Q266 | AIVSVQEIVDF | 3 | Homo sapiens, Mus musculus, Bos taurus | Q286 | LSREDQIALLK | 3 | Homo sapiens, Mus musculus, Bos taurus | Q424 | SVHSEQVFALR | 3 | Homo sapiens, Mus musculus, Bos taurus | R232 | RSFSDRLRVTP | 2 | Homo sapiens, Mus musculus | R232 | RSFSDQLRVTP | 1 | Bos taurus | R283 | FLQLSREDQIA | 3 | Homo sapiens, Mus musculus, Bos taurus | R305 | LETSRRYNPGS | 3 | Homo sapiens, Mus musculus, Bos taurus | S264 | ELAIVSVQEIV | 3 | Homo sapiens, Mus musculus, Bos taurus | T258 | RFAHFTELAIV | 3 | Homo sapiens, Mus musculus, Bos taurus | T302 | VMLLETSRRYN | 3 | Homo sapiens, Mus musculus, Bos taurus | V269 | SVQEIVDFAKQ | 3 | Homo sapiens, Mus musculus, Bos taurus | W443 | LLSEIWDVHE | 3 | Homo sapiens, Mus musculus, Bos taurus |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |